Rosalie Nolley
Overview
Explore the profile of Rosalie Nolley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1039
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jillson L, Rider L, Rodrigues L, Romero L, Karimpour-Fard A, Nieto C, et al.
Mol Cancer Res
. 2021 Apr;
19(7):1123-1136.
PMID: 33846123
Prostate cancer genomic subtypes that stratify aggressive disease and inform treatment decisions at the primary stage are currently limited. Previously, we functionally validated an aggressive subtype present in 15% of...
12.
Liu S, Garcia-Marques F, Zhang C, Lee J, Nolley R, Shen M, et al.
Sci Rep
. 2021 Apr;
11(1):7612.
PMID: 33828176
Prostate cancer remains the most common non-cutaneous malignancy among men in the United States. To discover potential serum-based biomarkers for high-risk prostate cancer, we performed a high-multiplex immunoassay utilizing patient-matched...
13.
Liu S, Shen M, Hsu E, Zhang C, Garcia-Marques F, Nolley R, et al.
Br J Cancer
. 2020 Dec;
124(5):896-900.
PMID: 33288843
Distinguishing clinically significant from indolent prostate cancer (PC) is a major clinical challenge. We utilised targeted protein biomarker discovery approach to identify biomarkers specific for pro-metastatic PC. Serum samples from...
14.
Sriram R, van Criekinge M, DeLos Santos J, Ahamed F, Qin H, Nolley R, et al.
Cancers (Basel)
. 2020 Mar;
12(3).
PMID: 32110965
Non-invasive assessment of the biological aggressiveness of prostate cancer (PCa) is needed for men with localized disease. Hyperpolarized (HP) C magnetic resonance (MR) spectroscopy is a powerful approach to image...
15.
Hsu E, Rice M, Bermudez A, Marques F, Aslan M, Liu S, et al.
Proc Natl Acad Sci U S A
. 2020 Jan;
117(4):2032-2042.
PMID: 31932422
Resistance to androgen deprivation therapy, or castration-resistant prostate cancer (CRPC), is often accompanied by metastasis and is currently the ultimate cause of prostate cancer-associated deaths in men. Recently, secondary hormonal...
16.
Vijayalakshmi K, Shankar V, Bain R, Nolley R, Sonn G, Kao C, et al.
Int J Cancer
. 2019 Dec;
147(1):256-265.
PMID: 31863456
Clear cell renal cell carcinoma (ccRCC) is the most common and lethal subtype of kidney cancer. Intraoperative frozen section (IFS) analysis is used to confirm the diagnosis during partial nephrectomy....
17.
Xiao Y, Zhao H, Tian L, Nolley R, Diep A, Ernst A, et al.
Cancer Res
. 2019 Oct;
79(22):5758-5768.
PMID: 31585940
Angiogenesis is a hallmark of cancer that promotes tumor progression and metastasis. However, antiangiogenic agents have limited efficacy in cancer therapy due to the development of resistance. In clear cell...
18.
Kristensen G, Drimer Berg K, Toft B, Stroomberg H, Nolley R, Brooks J, et al.
J Clin Pathol
. 2019 Jul;
72(10):696-704.
PMID: 31331953
Aims: Zinc-alpha 2-glycoprotein (AZGP1) is a promising tissue biomarker to predict outcomes in men undergoing treatment for localised prostate cancer (PCa). We aimed to examine the association between AZGP1 expression...
19.
Middleton L, Shen Z, Varma S, Pollack A, Gong X, Zhu S, et al.
JCI Insight
. 2019 May;
5.
PMID: 31094703
Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptoms in men. Current treatments target prostate physiology rather than BPH pathophysiology and are only partially effective....
20.
Spiciarich D, Nolley R, Maund S, Purcell S, Herschel J, Iavarone A, et al.
Angew Chem Int Ed Engl
. 2017 Jun;
56(31):8992-8997.
PMID: 28649697
Sialylated glycans are found at elevated levels in many types of cancer and have been implicated in disease progression. However, the specific glycoproteins that contribute to the cancer cell-surface sialylation...